Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Polynovo ( (AU:PNV) ) is now available.
PolyNovo Limited has appointed Mr. Robert Douglas as a Non-Executive Director to its Board. Mr. Douglas brings over 35 years of experience in medical device technology and public company governance, with a strong background in digital health and international business expansion. His previous roles at ResMed and current position with Globus Medical highlight his expertise in patient data management and cloud technology, which are expected to benefit PolyNovo’s strategic growth and innovation efforts.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.62 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive medical technology company based in Melbourne, Australia, specializing in products that simplify the management of acute complex wounds. The company is known for its NovoSorb range of bio-resorbable polymers, which are used in various medical applications, including dermal scaffolds for wound regeneration. PolyNovo has treated over 84,000 patients across 46 countries and is focused on growth through new products, indications, and markets.
Average Trading Volume: 3,386,217
Technical Sentiment Signal: Sell
Current Market Cap: A$1.03B
For an in-depth examination of PNV stock, go to TipRanks’ Overview page.